Skip to main content

Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19

References

  • Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, D.S.C., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382, 1708–1720.

    CAS  Article  Google Scholar 

  • Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

    CAS  Article  Google Scholar 

  • Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S.M., Lau, E.H.Y., Wong, J.Y., et al. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382, 1199–1207.

    CAS  Article  Google Scholar 

  • Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al. (2020). Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55, 102763.

    Article  Google Scholar 

  • Moon, C. (2020). Fighting COVID-19 exhausts T cells. Nat Rev Immunol 20, 277.

    CAS  Article  Google Scholar 

  • Piconi, S., Parisotto, S., Rizzardini, G., Passerini, S., Terzi, R., Argenteri, B., Meraviglia, P., Capetti, A., Biasin, M., Trabattoni, D., et al. (2011). Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 118, 3263–3272.

    CAS  Article  Google Scholar 

  • Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020). Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 71, 762–768.

    CAS  Article  Google Scholar 

  • Tang, N., Li, D., Wang, X., and Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18, 844–847.

    CAS  Article  Google Scholar 

  • Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020). Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369, m1849.

    Article  Google Scholar 

  • Torigoe, M., Sakata, K., Ishii, A., Iwata, S., Nakayamada, S., and Tanaka, Y. (2018). Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol 195, 1–7.

    CAS  Article  Google Scholar 

  • Vaninov, N. (2020). In the eye of the COVID-19 cytokine storm. Nat Rev Immunol 20, 277.

    CAS  Article  Google Scholar 

  • Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank the trial team members at Peking University First Hospital, Peking University People’s Hospital, the First Affiliated Hospital of Nanchang University and Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. We thank Dr. Yongchang Sun, Dr. Jinxia Zhao, Dr. Hongmei Jing, Dr. Xiaoguang Li, Dr Yahong Wang, Dr. Qinggang Ge, Dr. Chen Yao, Dr. Xiaoyan Yan, Dr. Wenle Zhao, Dr. Naiqing Zhao, Dr. Cheng Lv, Dr. Zijian Hu, Dr. Chang Liu and Dr. Lei Wang for the scientific discussion. We thank Shanghai Pharmaceutical Co., Ltd. and Guangdong ZhongSheng Pharmaceutical Co., Ltd. for providing the research drug. We thank all the members of the drug clinical trial center of Peking University Third Hospital for the whole project. This work was supported by MOST (Ministry of Science and Technology of the People’s Republic of China) foundation for SARS-CoV-2 Research (2020YFC0844500), the “13th Five-Year” National Science and Technology Major Project of China (2017ZX09101001-002-001, 2017ZX09304012), and Peking University Health Center Foundation for Combating the Pandemic Programs (BMU2020HKYZX011).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Dongyang Liu or Ning Shen.

Additional information

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, Q., Cui, C., Xu, F. et al. Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19. Sci. China Life Sci. 64, 660–663 (2021). https://doi.org/10.1007/s11427-020-1871-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11427-020-1871-4